People in the cannabis market are now focusing on several different cannabis compounds to develop new marijuana-based products.  THCA is a well-known compound that people now embrace.  People receive different benefits from using the chemical compound Tetrahydrocannabinolic acid THCA. This article will outline the benefits and uses of THCA Flower. 

What is THCA Flower?

THCA flower is raw cannabis with high levels of THCA. The product does not present psychoactive effective can be consumed raw. However, when it is exposed to heat it can present some side effects since it converts to THC. The idea shows that smoking it can present some THC effects.  A lot of people look for thca flower clearance deals to experience its benefits without spending more money. Raw cannabis products like THCA flower are widely known due to its different uses. 

Benefits of THCA Flower

• Anti-Inflammatory Properties

THCA is widely used for its ability in reducing inflammation. Therefore, if you often suffering from inflammatory conditions, then including THCA in your routine can boost your health outcomes. This can reduce the risks you are exposed to. 

Several studies show that THCA interacts with the body’s endocannabinoid system which regulates several physiological processes. This makes it a natural option for managing conditions like arthritis and muscle soreness. 

THCA have neuroprotective properties, making it an ideal option for people that want to seek support brain health. The idea shows that THCA can help you manage neurodegenerative conditions like Alzheimer.

Including THCA flower in your routine can help promote long-term cognitive wellness, helping you stay focused. For this reason, if you need to explore its benefits and affordability, then THCA Flower Clearance is an ideal choice for you. 

Uses of THCA Flower

You can enjoy THCA flower by consuming it raw. You can also choose to add it in smoothies, juices, or salad for a nutrient-packed addition to your diet. Consuming the product raw help preserves its compound, allowing you to enjoy the required benefits without incurring any psychoactive implications. 

If you are a wellness enthusiast, then this product is the best option to include in your daily life. Its naturalness complements different recipes, which can be beneficial, especially if you love herbal meals. 

Furthermore, THCA flows can be used to make homemade tropical products like cream or salved. These products are used to soothe pain and inflammation when applied directly. 

Experimenting different preparations can help you create a customized solution that addresses your specific needs. Combining THCA with natural ingredients like coconut oil or essential oils can increase the soothing effect. 

Therefore, a THCA flower is a popular product in the cannabis industry due to its increased benefits and uses. It contains anti-inflammatory and neuroprotective properties, which present potential health benefits for people with different needs. Examining these products through THCA Flower Clearance options can offer you ideal insights into its advantages without breaking the banks. If you are new to cannabis, then thca flower clearance can be the best option to choose.

In a move that has sparked significant controversy within the cannabis industry and among reform advocates, Republican Senators James Lankford (Oklahoma) and Pete Ricketts (Nebraska) have introduced a bill that seeks to permanently enforce the tax penalties imposed on cannabis businesses under Section 280E of the Internal Revenue Code. The legislation, titled the “No Deductions for Marijuana Businesses Act,” was filed on February 7, 2025, and aims to ensure that marijuana operators remain unable to deduct standard business expenses, even if marijuana is rescheduled under federal law.

The proposal comes at a time when cannabis reform advocates have been pushing for fairer tax policies and greater federal recognition of the legal cannabis industry. However, this bill represents a significant obstacle to those efforts, as it would effectively maintain one of the most burdensome financial restrictions on cannabis businesses indefinitely. This article explores the implications of the proposed legislation, its potential impact on the cannabis industry, and the broader context of federal marijuana policy reform.

 What Is Section 280E?

Section 280E of the Internal Revenue Code is a decades-old provision that has long been a thorn in the side of legal cannabis operators. Enacted in 1982 during the height of the War on Drugs, Section 280E prevents businesses involved in trafficking Schedule I or II controlled substances from deducting ordinary and necessary business expenses from their taxable income. This includes expenses such as rent, payroll, utilities, advertising, and other operational costs.

The provision was originally designed to target illegal drug dealers but has since been applied to state-legal cannabis businesses due to marijuana’s classification as a Schedule I drug under the Controlled Substances Act (CSA). As a result, cannabis operators are subject to significantly higher effective tax rates compared to businesses in other industries. In some cases, these tax rates can reach as high as 70% to 90%, leaving many cannabis companies struggling to stay afloat despite generating substantial revenue.

For years, cannabis advocates have argued that Section 280E is outdated and unfairly penalizes businesses that operate legally under state laws. They contend that removing or modifying this provision would allow cannabis companies to reinvest in their operations, create jobs, and contribute more effectively to local economies.

The “No Deductions for Marijuana Businesses Act”

The bill introduced by Senators Lankford and Ricketts seeks to cement Section 280E’s application to cannabis businesses permanently. Specifically, it would ensure that even if marijuana is rescheduled from its current classification as a Schedule I drug—something reform advocates have been pushing for—cannabis operators would still be barred from deducting standard business expenses.

In a statement accompanying the bill’s introduction, Senator Lankford said: 

”Marijuana doesn’t make our families stronger, our streets safer, or our workplaces more productive. Businesses that sell federally illegal drugs—including marijuana businesses—shouldn’t get federal tax breaks.”

Senator Ricketts echoed this sentiment, emphasizing his opposition to what he described as efforts to “normalize” marijuana use: 

”We cannot allow federal tax policy to subsidize an industry that poses serious risks to public health and safety.”

The bill reflects a broader ideological stance among certain Republican lawmakers who remain staunchly opposed to cannabis legalization at both the state and federal levels. By targeting one of the key financial incentives for rescheduling or descheduling marijuana—namely, relief from Section 280E’s tax penalties—the legislation seeks to undermine efforts to legitimize the industry.

 Implications for Cannabis Businesses

If enacted, the “No Deductions for Marijuana Businesses Act” would deal a significant blow to cannabis operators already grappling with high taxes and regulatory challenges. Many in the industry were hopeful that rescheduling marijuana—such as moving it from Schedule I to Schedule III under the CSA—would alleviate some of these burdens by rendering Section 280E inapplicable. However, this bill would ensure that those hopes are dashed.

Financial Strain on Operators

The inability to deduct ordinary business expenses means that cannabis companies are taxed on their gross income rather than their net income. This creates an unsustainable financial model for many operators, particularly small and medium-sized businesses that lack access to traditional banking services or capital due to federal prohibition.

For example:

 A dispensary with $1 million in revenue might incur $800,000 in operating expenses. Under normal tax rules, it would pay taxes on $200,000 in profit. However, because of Section 280E, it must pay taxes on the full $1 million in revenue. With effective tax rates often exceeding 70%, this leaves little room for reinvestment or growth—and in some cases leads to insolvency.

By keeping these restrictions permanently intact, Lankford and Ricketts’ bill could exacerbate existing disparities within the industry. Larger multi-state operators (MSOs) with significant resources may be able to weather these challenges better than smaller independent businesses or social equity applicants seeking entry into the market.

 Impact on State-Legal Markets

The financial strain imposed by Section 280E also has broader implications for state-legal cannabis markets. High taxes and operating costs make it difficult for legal businesses to compete with illicit operators who do not face similar financial constraints. This undermines one of the primary goals of legalization: reducing the size of the illegal market.

According to Beau Whitney, Chief Economist at Whitney Economics: 

”Maintaining 280E restrictions will only perpetuate an uneven playing field where illicit operators thrive while legal businesses struggle.”

States that rely on tax revenue from legal cannabis sales could also feel the impact. If legal operators are forced out of business due to unsustainable tax policies, states could see declines in revenue earmarked for education, healthcare, infrastructure projects, and other public services funded by cannabis taxes.

Opposition From Advocates and Industry Leaders

The introduction of this bill has drawn sharp criticism from cannabis advocates and industry leaders who view it as a regressive step that ignores both economic realities and shifting public opinion on marijuana legalization.

Advocacy Groups Speak Out

Organizations such as the National Cannabis Industry Association (NCIA) and Marijuana Policy Project (MPP) have condemned Lankford and Ricketts’ proposal. In a statement released shortly after the bill’s introduction, NCIA Executive Director Aaron Smith said: 

”This legislation represents an outdated approach rooted in stigma rather than science or common sense. It unfairly targets an industry that Is creating jobs, generating tax revenue, and providing safe access for millions of Americans.”

Similarly, MPP’s Deputy Director Matthew Schweich argued: 

”Punitive tax policies like 280E only serve to bolster the illicit market while undermining legitimate businesses trying to operate within state laws.”

Industry Leaders React

Cannabis business owners have also voiced their concerns about how this legislation could impact their operations. Many argue that fair tax treatment is essential not only for their survival but also for fostering innovation and competition within the industry.

Kim Rivers, CEO of Trulieve Cannabis Corp., stated:  ”The legal cannabis industry has proven its value time and again through job creation and community investment. Policies like this threaten all of that progress.”

 Broader Context: Federal Rescheduling Efforts

The timing of this bill is particularly notable given ongoing discussions about rescheduling marijuana at the federal level. In late 2023, President Joe Biden directed federal agencies—including the Department of Health and Human Services (HHS) and Drug Enforcement Administration (DEA)—to review marijuana’s classification under the CSA. HHS subsequently recommended moving marijuana from Schedule I (the most restrictive category) to Schedule III.

Rescheduling marijuana would represent a significant shift in federal policy by acknowledging its medical value while reducing some regulatory barriers. However, it would not legalize marijuana outright or address issues like banking access or interstate commerce.

Advocates had hoped that rescheduling would also eliminate Section 280E’s application to cannabis businesses—a key incentive for reform efforts. By introducing legislation specifically designed to preserve these tax penalties regardless of rescheduling outcomes, Lankford and Ricketts are effectively preempting one of the potential benefits of reform.

Conclusion

The “No Deductions for Marijuana Businesses Act” introduced by Senators James Lankford and Pete Ricketts represents a significant challenge for advocates seeking fairer treatment for legal cannabis operators under federal law. By aiming to keep Section 280E’s tax penalties permanently intact—even if marijuana is rescheduled—the bill threatens to undermine progress toward legitimizing an industry that has already faced numerous obstacles. While proponents argue that such measures are necessary to prevent “subsidizing” an industry they oppose on moral grounds, critics contend that maintaining punitive tax policies will only harm legitimate businesses while empowering illicit markets.

As debates over federal marijuana policy continue—including discussions around rescheduling—it remains crucial for stakeholders within the cannabis industry to mobilize against regressive measures like this one. The future of America’s rapidly evolving relationship with cannabis hangs in the balance—and decisions made now will shape its trajectory for years to come.

MORE ON 280E, IT KILLS CANNABIS, READ ON…

WHAT IS THE IRS 280E TAX CODE AND WHAT DOES IT MEAN?

Late-Stage Dementia: Not A Hopeless Case, If You Medicate With Marijuana

Late-stage dementia refers to the end or final stage of cognitive decline associated with dementia.

During this stage, patients go through severe memory loss and significant impairment of cognitive function, which affects communication and language abilities, memory, judgment, and reasoning. Patients in late-stage dementia are typically disoriented, impaired, and incontinent – thus, are completely dependent on their caregivers. Physically, the body goes through extreme weight loss and is much more prone to infections and bedsores among other symptoms.

Unfortunately, once one has reached the final stage of dementia, there is no known cure. Caregiving or management is typically focused on improving ones’ quality of life instead of treating the condition.

However, it seems that cannabis might be able to help.

The Case For Using CBD

A 2023 study from Greece involved researchers administering a CBD tincture on dementia patients revealed some incredible results. The findings, which were published in the medical journal, Clinical Gerontologist, found the administration of 3% CBD tinctures to be safe and effective for treating both psychological and behavioral symptoms associated with dementia.

A group of 20 patients were involved; 10 of them were given CBD for a period of 6 months and the other half underwent conventional dementia treatment. “The follow-up assessment… showed significant improvement of BPSD [behavioral and psychological symptoms of dementia] in all our patients who received CBD, and no or limited improvement in the second group, regardless of the underlying neuropathology of dementia,” they said.

“We suggest that CBD may be a more effective and safe choice for managing BPSD than the typical intervention,” the investigators concluded. “Healthcare professionals should consider incorporating it into their practices to reduce BPSD in PwD [people with dementia]… Future large and randomized clinical trials are needed to reassure these findings,” they said.

Another study from 2022 found positive results from using CBD extracts, but this time for reducing agitation caused by dementia. Agitation as well as aggression are some of the more distressing symptoms of dementia, which can manifest in different ways including physical violence, verbal outbursts, pacing, and restlessness. While there is no one standard cure for it, it’s believed that this behavior can be caused by the progressive brain cell damage associated with dementia, which makes it difficult for patients to understand and interpret their environment.

The study from Israel involved researchers administering plant-based CBD extracts with a 30:1 ration of CBD to THC on a cohort of senior dementia patients with a mean age of 79.

“Patients in the investigational group experienced a significantly greater reduction in sleep disturbances, and in agitation and aggression sub-score using two different measurement tools. The improvements were accompanied with non-serious side effects,” said the authors. “We recommend conducting a large scale randomized controlled trial on behavioral disturbances related to dementia and to compare clinical sub-types of dementia,” they reported.

THC Studies

Meanwhile, there have been other studies that have found success in treating the symptoms of dementia with THC. In 2023, a case study conducted by researchers from the Tulane University School of Medicine together with investigators at the University of Texas discussed the findings of using a high-THC tincture on an 85-year old patient with dementia.

The participant’s dementia symptoms gradually became worse over time, and wasn’t responding to medications. However, after administering the THC medicine, they found that the “patient’s behavior rapidly improved” and the marked benefits were so significant that the patient was discharged from a treatment facility to home care.

The Need For More Studies

Researchers from the University of Kentucky started a clinical trial analyzing the impact of medical cannabis on patients who were already in late-stage dementia. According to Greg Jicha, MD, Ph.D., a neurologist as well as the director of clinical trials at the Sanders-Brown Center on Aging in the United Kingdom: “The idea really came on the basis of a patient whose name was Libby, and she was cared for by a friend and colleague nationally.”  According to Jicha, there is a great need to develop other treatments for late-stage dementia, and there is a potential seen in medical marijuana.

“We have very few medicines used to provide comfort in the later stages of dementia. While the field is largely focused on finding ways to prevent or potentially slow or stop the disease in its early stages, we’ve forgotten about those later-stage patients that aren’t eligible for those types of treatments,” explains Jicha. He also adds that much more research and participants are needed.

“It has been available, and we have been enrolling folks in this study who are in the late stages of disease since June, but we need hundreds or more nationally to fill that trial to get the medical data that we need to potentially, in the future, get dementia on the list of conditions that are eligible for medical marijuana,” said Jicha. Furthermore, he explains that the current available treatments are only sedatives, but he thinks there are other ways this can be managed.

“Our ultimate goal is not sedate and render unconscious these patients so that they feel nothing but rather provide them comfort and relief that allows them to engage in their final years of life,” said Jicha.

CONCLUSION

While there are many studies showing potential and promise for using various compounds in cannabis for the treatment of dementia, research is still limited and most studies feature small sample sizes. That said, cannabis has certainly proven to be safe so far, but families of the affected patients are encouraged to seek consultations with medical professionals before using cannabis as a treatment option for dementia.

CANANBIS AND DEMENTIA, READ ON…

WHAT WE NOW KNOW ABOUT CANNABIS AND DEMENTIA!